Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Overview

Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical company dedicated to the discovery and development of innovative oncology therapies. Founded in 2015 and based in Beijing, China, Jacobio emphasizes the in-house invention and advancement of new treatments aimed at various cancers. With a focus on addressing the unmet medical needs in oncology, Jacobio's research and development efforts span across several promising molecular targets and pathways. The company's portfolio features clinical-stage allosteric SHP2 inhibitors and other novel compounds targeting critical oncogenic drivers. Through strategic collaboration, notably with AbbVie Ireland Unlimited Company for SHP2 inhibitors, Jacobio aims to leverage partnerships to enhance its development pipeline and accelerate the availability of breakthrough therapies to patients globally.

Products and Services

Jacobio Pharmaceuticals is actively developing a range of pioneering oncology therapies, including:

• JAB-3312 and JAB-3068 – Clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors targeting the treatment of esophageal cancer. SHP2 plays a pivotal role in the activation of pathways essential for cancer cell growth and survival, making it a promising target for cancer treatment.
• JAB-8263 – A small molecule inhibitor of BET family proteins. By inhibiting the BET proteins, JAB-8263 disrupts the expression of MYC, a gene implicated in the proliferation and survival of cancer cells, offering a strategy to combat various cancers.
• JAB-21822 – This oral small molecule specifically targets the mutant KRAS G12C protein, a notorious driver of cancer progression in various solid tumors. Targeted inhibition of KRAS G12C presents a novel approach to tackling these challenging cancer subtypes.
• JAB-BX102 – A humanized inhibitory antibody against human CD73, designed for the treatment of PD-(L)1 resistant cancer. CD73 is involved in the suppression of anti-tumor immune responses, and its inhibition can potentially restore immune activity against tumors.
• JAB-2485 – An aurora A kinase inhibitor for the treatment of solid tumors. Aurora A kinase is critical for cell division, and its inhibition can hinder the proliferation of cancer cells.
• JAB-24114 – Targets the tumor metabolic pathway, offering a novel therapeutic strategy for the treatment of solid tumors by disrupting their metabolic processes.
• JAB-BX300 – A molecule antibody targeting the RAS pathway, particularly geared towards treating pancreatic and other solid tumors with KRAS mutations. This approach aims to inhibit the downstream signaling pathways activated by mutant RAS proteins, thereby impeding tumor growth.

Through these innovative drug candidates, Jacobio Pharmaceuticals Group Co., Ltd. endeavors to provide new treatment options for patients battling diverse forms of cancer, emphasizing its commitment to addressing the ongoing challenges in oncology.